Elicio Therapeutics (NASDAQ:ELTX) stock is taking off on Tuesday after the company posted updated preliminary results from a Phase 1 clinical trial.
The study focuses on ELI-002 2P as a monotherapy for solid tumors from pancreatic and colorectal cancers. Promising results show T-cell responses in 21 of 25 patients, and biomarker clearance was seen in six out of 25 patients.
Christopher Haqq, executive vice president, head of research and development, as well as the chief medical officer of Elicio Therapeutics, said the following about the clinical trial results:
“Our lymph node-targeted cancer vaccine candidate induced direct ex vivo mKRAS-specific T cell responses in 84% of patients, with 59% of patients demonstrating a response with two key types of T cells – helper cells and killer cells. Past studies have not seen this large a fraction of patients respond, this high a magnitude of a response or the expansion of both key populations of T cells.”
ELTX Stock Reactions on Tuesday
With this positive clinical trial update comes heavy trading of ELTX stock on Tuesday. As of this writing, more than 5.4 million shares of the company’s stock have traded as investors celebrate the news. To put that number in perspective, the stock’s daily average trading volume is closer to just 20,000 shares.
ELTX stock is up 11.3% as of Tuesday morning!
Investors seeking out even more of the most recent stock market stories are going to want to stick around!
We have all of the hottest market news worth reading about on Tuesday! Among that is what’s happening with shares of Sentage (NASDAQ:SNTG) stock, the biggest pre-market stock movers this morning and more. All of that news is ready to go at the links below!
More Stock Market News for Tuesday
- Why Is Sentage (SNTG) Stock Up 86% Today?
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
- Dear AAPL Stock Fans, Mark Your Calendars for Jan. 19
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
